Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-8068 in combination with antitumor therapy for advanced renal cell carcinoma
CTR20254565Phase 2Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CS1002 in renal cell carcinoma (RCC), sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Jan 2026; status: active.
02
Drugs
CS1002
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on CTR20254565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254565.